Tiruvoipati Ravindranath, Reddy Mallikarjuna Ponnapa, Paul Eldho, Gupta Sachin, Subramaniam Ashwin, Zhang David, Haji Kavi
Department of Intensive Care, Peninsula Health, Frankston, VIC, 3199, Australia.
Division of Medicine, Peninsula Clinical School, Monash University, Frankston, VIC, Australia.
Eur J Med Res. 2025 Mar 26;30(1):205. doi: 10.1186/s40001-025-02447-0.
High-flow nasal cannulae (HFNC) are often used for oxygen delivery in intensive care units (ICU). A new configuration HNFC, the Duet HFNC, can deliver higher pressures and potentially improve gas exchange. The clinical performance, safety and patient comfort of these Duet cannula are unclear. Furthermore, there is no data on performance of conventional or Duet HFNC in patients with nasogastric tubes (NG) or between male and female patients. We compared the gas exchange, tolerance, and comfort with conventional and Duet HFNC.
This single-center, open labeled randomized crossover study included invasively ventilated patients who were extubated. Patients were randomized to protocol A (n = 25; Duet cannula for 30 min followed by conventional HFNC for 30 min) or protocol B (n = 25; conventional followed by Duet HFNC). Subgroup analysis included comparisons between patients with and without a NG, and between male and female patients when receiving Duet and conventional HFNC. During the study period the HFNCs flow rates were set at 40 L/min with the same FiO standardizing the comparisons for both cannulas.
There was no significant difference in PaO (86.8 [22.2] vs. 88.9 [23.5]; p = 0.38), PaCO (37.7 [3.9] vs. 37.8 [3.9]; p = 0.81) and SaO (96.2% [2.0] vs. 96.4% [1.8]; p = 0.32), comfort and tolerance between the Duet and conventional HFNC. The subgroup analysis did not show a significant difference between these cannulas in patients with or without nasogastric tubes or between males and females.
Duet HFNC is comparable to conventional HFNC. Further studies on higher flow rates and for longer period are warranted to determine the utility of Duet cannula.
This trial was registered with ClinicalTrials.gov (Number: NCT06398951) on 3rd May 2024- Retrospectively registered.
高流量鼻导管(HFNC)常用于重症监护病房(ICU)的氧疗。一种新的配置HFNC,即Duet HFNC,能够输送更高的压力,并可能改善气体交换。这些Duet鼻导管的临床性能、安全性和患者舒适度尚不清楚。此外,关于常规或Duet HFNC在有鼻胃管(NG)的患者中或男性与女性患者之间的性能尚无数据。我们比较了常规HFNC和Duet HFNC的气体交换、耐受性和舒适度。
这项单中心、开放标签随机交叉研究纳入了已拔管的有创通气患者。患者被随机分为方案A(n = 25;先使用Duet鼻导管30分钟,然后使用常规HFNC 30分钟)或方案B(n = 25;先使用常规HFNC,然后使用Duet HFNC)。亚组分析包括有和没有鼻胃管的患者之间,以及接受Duet和常规HFNC时男性和女性患者之间的比较。在研究期间,HFNC的流速设定为40 L/分钟,两种鼻导管的比较采用相同的FiO进行标准化。
Duet HFNC和常规HFNC在动脉血氧分压(86.8 [22.2] 对88.9 [23.5];p = 0.38)、动脉血二氧化碳分压(37.7 [3.9] 对37.8 [3.9];p = 0.81)和血氧饱和度(96.2% [2.0] 对96.4% [1.8];p = 0.32)、舒适度和耐受性方面无显著差异。亚组分析未显示在有或没有鼻胃管的患者中或男性与女性之间,这些鼻导管存在显著差异。
Duet HFNC与常规HFNC相当。有必要对更高流速和更长时间进行进一步研究,以确定Duet鼻导管的效用。
该试验于2024年5月3日在ClinicalTrials.gov注册(编号:NCT06398951)——回顾性注册。